Chair(s): Merel Hellemons, David Baldwin
Session type: Experts interview
ARGYRIS TZOUVELEKIS, Stefano Gasparini
Session content
Argyris Tzouvelekis
Replay
Slides
Discussion and Q&A
Argyris Tzouvelekis
Stefano Gasparini
Replay
Slides
Session aims
To review the incidence and risk factors of pulmonary toxicity associated with new oncology drugs, with particular focus on patients with pre-existing interstitial lung disease (ILD); to highlight the importance of early recognition, awareness, and close monitoring of high-risk groups; to emphasize the role of the multidisciplinary team (MDT) in the evaluation and management of suspected drug-induced pulmonary toxicity; to outline key steps in the diagnostic pathway, including exclusion of alternative diagnoses and severity stratification; to discuss current management strategies, particularly the role of oral corticosteroids, and the importance of appropriate dosing in the setting of immune checkpoint inhibitor–induced toxicity.